Skip to main content

Joltid

Popular

Lynk Pharmaceuticals Announces First Patient Dosed in Phase II Clinical Trial of LNK01004 Ointment for Vitiligo

HANGZHOU, China, SHANGHAI and BOSTON, July 8, 2026 /PRNewswire/ — Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on immune and inflammatory diseases, today announced that the first patient was successfully dosed on June…

Read the full release →

News provided by PR Newswire.